Aptima® Sexual and Vaginal Health Solutions
The most comprehensive sexual and vaginal health molecular menu.
Hologic offers the most comprehensive sexual and vaginal health portfolio that allows you to automate molecular testing workflows while instilling confidence in your clinical results.
One Sample, Multiple Results
With innovative nucleic acid amplification test (NAAT) and a single collection device, the Aptima® Multitest Swab simplifies testing by helping to detect up to 7 infections and disease states from just 1 vaginal swab.1-5
Through continuous clinical research and trusted testing solutions, Hologic supports our partners in the fight against sexually transmitted infections (STIs) and accurate detection of vaginitis.
Our sexual and vaginal health portfolio leverages best-in-class technology to provide timely and reliable results to patients.
The Aptima sexual and vaginal health portfolio can run alongside multiple disease areas on our fully automated Panther® Scalable Solutions.
Evolve Your Offerings with Aptima Assays
7 infections and disease states
can be detected with the Aptima sexual and vaginal health portfolio to support your testing needs.
35 years of experience
in sexual and vaginal health molecular testing and helping stop the spread of disease.
A Comprehensive, Flexible Menu
Detects chlamydia and gonorrhea from a single sample. By using this highly specific and sensitive test, laboratories can improve workflow while allowing healthcare professionals to identify and treat patients with these often-asymptomatic infections to prevent long-term health consequences.1
When identifying Mycoplasma genitalium, the test you choose matters. A highly sensitive rRNA test is needed for an accurate diagnosis, and NAAT is the most effective way to identify this STI. Hologic developed the first FDA-cleared sample-to-result test to detect this highly prevalent STI.2
The Latest News on Aptima Sexual and Vaginal Health
Increasing Certainty in Sexual & Vaginal Health
The Aptima sexual and vaginal health portfolio represents a comprehensive menu to champion women’s health worldwide. By supporting sexual health testing with innovative technology and a fully automated, sample-to-result platform, we are helping advance early detection and treatment.
Hologic is committed to protecting sexual and reproductive health by preventing the spread of STIs and vaginitis. We are continuously investing in R&D efforts designed to deliver new products to help healthcare providers and laboratories provide better patient care, now and in the future.
First FDA-Cleared STI Molecular Test
FDA clears the first molecular diagnostic test kit for an STI: the Aptima Combo 2 assay for chlamydia and gonorrhea (CT/NG).
Aptima HPV assay
Aptima HPV assay is the first FDA-cleared test for human papillomavirus (HPV) mRNA, and the test detects mRNA in 14 high risk HPV types associated with cervical cancer.
Panther System Introduced
FDA clears the Panther system, an automated, integrated molecular platform, for use with the Aptima Combo 2 assay. Today, this scalable instrument supports labs with a robust menu of 20+ assays.
Hologic receives FDA clearance for the Aptima HPV 16/18/45 Genotype assay on its Tigris system. This assay was the first test FDA-cleared for genotyping HPV types 16, 18 and/or 45.
Aptima Trichomonas vaginalis assay
Hologic introduces the FDA-cleared Aptima Trichomonas vaginalis assay for the identification of Trichomonas vaginalis (TV), the most common curable STI with a prevalence higher than CT and NG combined.7
Aptima HSV 1 & 2 assay
The Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay receives FDA clearance to qualitatively detect, and differentiate between, HSV-1 and HSV-2.
Aptima Zika Virus assay
The FDA issues an Emergency Use Authorization (EUA) to authorize the use of the Aptima Zika Virus assay for the in vitro qualitative detection of Zika virus.8
Aptima M. gen assay
FDA clears the Aptima Mycoplasma genitalium assay, the first FDA-cleared test to detect this under-recognized but highly prevalent STI.
Aptima BV and CV/TV assays
The FDA granted clearance for the Aptima BV and Aptima CV/TV assays, which provide an accurate and objective method for diagnosing vaginitis.